Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.
Jan. 30, 2023 – When he was a young boy growing up in Brooklyn, Anthony Fauci loved playing sports. As captain of his high school basketball team, he wanted to be an athlete, but at 5-foot-7, he says it wasn’t in the cards. So, he decided to become a doctor instead.
Fauci, who turned 82 in December, stepped down as the head of the National Institute of Allergy and Infectious Diseases that same month, leaving behind a high-profile career in government spanning more than half a century, during which he counseled seven presidents, including Joe Biden. Fauci worked at the National Institutes of Health for 54 years and served as director of the National Institute of Allergy and Infectious Diseases for 38 years. In an interview last week, he spoke to WebMD about his career and his plans for the future.
This interview has been edited and condensed.
It‘s only been a few weeks since your official “retirement,“ but what‘s next for you?
Almost certainly, I’ll begin working on a memoir. So that’s what I’d like to do over the next few years.
Are you looking forward to going back and seeing patients and being out of the public eye?
I will almost certainly associate myself with a medical center, either one locally here in the Washington, DC, area or some of the other medical centers that have expressed an interest in my joining the faculty. I am not going to dissociate myself from clinical medicine, since clinical medicine is such an important part of my identity and has been thus literally for well over 50 years. So, I’m not exactly sure of the venue in which I will do that, but I certainly will have some connection with clinical medicine.
What are you looking forward to most about going back to doctoring?
Well, I’ve always had a great deal of attraction to the concept of medicine, the application of medicine. I have taken care of thousands of patients in my long career. I spent a considerable amount of time in the early years of HIV, even before we knew it was HIV, taking care of desperately ill patients. I’ve been involved in a number of clinical research projects, and I was always fascinated by that because there’s much gratification and good feeling you get when you take care of, personally, an individual patient, when you do research that advances the field, and those advances that you may have been a part of benefit larger numbers of patients that are being taken care of by other physicians throughout the country and perhaps even throughout the world.
So those are all of the aspects of clinical medicine that I want to encourage younger people that these are the opportunities that they can be a part of, which can be very gratifying and certainly productive in the sense of saving lives.
Looking back over your career, what were some of the highs and lows, or turning points?
I first became involved in the personal care and research on persons with HIV, literally in the fall of 1981. [That was] weeks to months after the first cases were recognized. My colleagues and I spent the next few years taking care of desperately ill patients, and we did not have effective therapies because the first couple of years, we did not even know what the ideologic agent was. Even after it was recognized after 1983 and 1984, it took several years before effective therapies were developed, so there was a period of time where we were in a very difficult situation. We were essentially putting Band-Aids on hemorrhages, metaphorically, because no matter what we did, our patients continued to decline. That was a low and dark period of our lives, inspired only by the bravery and the resilience of our patients. A very high period was in [the late 1990s] and into the next century [with the development] of drugs that were highly effective in prolonged and effective suppression of viral loads to the point where people who were living with HIV, if they had access to therapy, could essentially lead a normal lifespan.
We put together the President’s Emergency Plan for AIDS Relief program known as PEPFAR, which now, celebrating its 20th anniversary, has resulted in saving 20-25 million lives. So, I would say that is … the highest point in my experience as a physician and a scientist, to have been an important part in the development of that program.
Do you feel like there‘s any unfinished business? Anything you would change?
Certainly, there’s unfinished business. One of the goals I would have liked to have achieved, but that is going to have to wait another few years, is the development of a safe and effective vaccine for HIV. A lot of very elegant science has been done in that regard, but we’re not there yet, it’s a very challenging scientific problem.
The other unfinished business is some of the other diseases that cause a considerable amount of morbidity and mortality globally, diseases like malaria and tuberculosis. We’ve made extraordinary progress over the 38 years that I’ve been director of the institute We have a vaccine, though it isn’t a perfect vaccine [for malaria]; we have monoclonal antibodies that are now highly effective in preventing malaria; we have newer drugs, better drugs for tuberculosis, but we don’t have an effective vaccine for tuberculosis. So, malaria vaccines, tuberculosis vaccines, those are all unfinished business. I believe we will get there.
These new COVID-19 variants keep getting more and more contagious. Do you see the potential for a serious new variant that could plunge us back into some level of public restrictions?
Anything is possible. One cannot predict, exactly, what the likelihood of getting yet again another variant that’s so different that it eludes the protection that we have from the vaccines and from prior infection. Again, I can’t give a number on that. I don’t think it’s highly likely that will happen.
Ever since Omicron came well over a year ago, we have had sublineages of Omicron that progressively seem to elude the immune response that’s been developed. But the one thing that’s good and has been sustained is that protection against severity of disease seems to hold out pretty well. I don’t think that we should be talking about restrictions in the sense of draconian methods of shutting things down; I mean, that was only done for a very brief period of time when our hospitals were being overrun. I don’t anticipate that that is going to be something in the future, but you’ve got to be prepared for it. There are some things that have been highly successful, and that is the vaccines that were developed in less than 1 year. And now, our challenge is to get more people to get their updated boosters.
There‘s already been criticism of the FDA‘s discussion of an annual COVID-19 vaccine. One criticism is that the COVID vaccines‘ effectiveness appears to wane after several months, so it would not offer protection for much of the year. Is that a legitimate criticism?
There’s no perfect solution to keeping the country optimally protected. I believe that it gets down to, “It’s not perfect, but don’t let the perfect be the enemy of the good.” We want to get into some regular cadence to get people updated with a booster that is hopefully managed reasonably well to what the circulating variant is. There are certainly going to be people – perhaps the elderly, some of the immune-compromised, and perhaps children – who will need a shot more than once per year, but the FDA’s leaning towards getting a shot that is [timed] with the flu shot, would at least bring some degree of order and stability to the process of people getting into the regular routine of keeping themselves updated and protected to the best extent possible.
Do you think we need to move on from mRNA vaccines to something that hopefully has longer-lasting protection?
Yes, we certainly want next-generation vaccines – both vaccines that have a greater degree of breadth, namely covering multiple variants, as well as a greater degree of duration. So, the real question is, “Is it the mRNA vaccine platform that is inducing a response that is not durable, or is the response against coronaviruses not a durable response?” That’s still uncertain. Yes, we need to do better with a better platform, or an improvement on the platform; that could mean adding adjuvants, that could mean a [nasal] vaccine in addition to a systemic vaccine.
Do you always wear a mask when you go out into the world? How do you evaluate the relative risk of situations when you go out in public?
I’ve been vaccinated, doubly boosted, I’ve gotten infected, and I’ve gotten the bivalent boost. So, I evaluate things depending upon what the level of viral activity is in the particular location where I’m at. If I’m going to go on a plane, for example, I have no idea where these people are coming from, I generally wear a mask on a plane. I don’t really go to congregate settings often. Many of the events I do go to are situations where a requirement for [attending] is to get a test that’s negative that day.
When you’re in a situation like that, even if it’s a crowded congregant setting, I don’t have any problem not wearing a mask. But when I’m unsure of what the status is and I might be in an area where there is a considerable degree of viral activity, I would wear a mask. I think you just have to use [your] judgment, depending on the circumstances that you find yourself in.
Doctors and health care professionals have been through hell during COVID. Do you think this might bring a permanent change to how doctors perceive their jobs?
Health care providers have been under a considerable amount of stress because this is a totally unprecedented situation that we find ourselves in. This is the likes of which we have not seen in well over 100 years. I hope this is not something that is going to be permanent, I don’t think it is, I think that we are ultimately going to get to a point where the level of virus is low enough that it’s not going to disrupt either society or the health care system or the economy.
We’re not totally there yet. We’re still having about 500 deaths per day, which is much, much better than the 3,000 to 4,000 deaths that we were seeing over a year ago, but it is still not low enough to be able to feel comfortable.
As a scientist, even a semi-retired one, what scares you? What wakes you up at night with worry?
The same thing I have been concerned about for, you know, 40 years: the appearance of a highly transmissible respiratory virus that has a degree of morbidity and mortality that could really be very disruptive of us in this country and globally. Unfortunately, we’re in the middle of that situation now, finishing our third year and going into year 4. So what worries me is yet another pandemic. Now that could be a year from now, 5 years from now, 50 years from now. Remember, the last time a pandemic of this magnitude occurred was well over 100 years ago. My concern is that we stay prepared. [We may] not necessarily prevent the emergence of a new infection, but hopefully we can prevent it from becoming a pandemic.
Anthony Fauci, MD, interview, Jan. 27, 2023.
Source: Read Full Article